People who live with celiac disease know the constant pressure of a strict gluten-free lifestyle.
Accidental contamination at restaurants, social meals, travel, and everyday food choices can still trigger symptoms and intestinal damage even when patients follow the diet carefully.
A new experimental drug now offers early hope that this rigid daily vigilance might become less stressful.
First Tracks Biotherapeutics’ ANB033 protected against gluten-caused intestinal injury and prevented symptom spikes in a small trial.
The findings suggest the treatment could ease the burden of strict gluten-free living by reducing the risk that comes with unavoidable exposure, without replacing the diet itself.
First Tracks Biotherapeutics develops ANB033 as an experimental treatment for celiac disease. Researchers enrolled 32 patients who had received a celiac diagnosis at least one year earlier. These participants followed a gluten-free diet yet still showed moderate intestinal damage on biopsies.
Even trace amounts of gluten can cause injury and debilitating symptoms despite careful efforts to avoid it. The study team gave patients three subcutaneous injections of ANB033 or a placebo at the start of the trial, at week two, and at week four.
Participants then consumed six grams of gluten daily for two weeks, roughly the amount in two slices of bread. Biopsies taken at the end of the study revealed statistically significant protection against intestinal damage in the ANB033 group compared with the placebo group.
Key outcomes include:
Study leader Dr. Benjamin Lebwohl of New York-Presbyterian, Columbia University Irving Medical Center described the dual benefit as remarkable. For the first time, a single study delivered both statistically significant prevention of symptoms and clear intestinal protection.
Also Read: World Heart Day 2026: 8 Ways to Protect Your Heart Every Day
ANB033 inhibits two immune cell proteins, IL-15 and IL-2. These proteins drive the inflammation that damages the intestine in celiac disease. IL-2 also links closely to the development of symptoms. Blocking these drivers, the drug reduces the body’s harmful reaction when gluten appears.
A strict gluten-free diet remains the primary way to manage celiac disease. Yet complete avoidance proves difficult in daily life. Restaurants, shared kitchens, packaged foods, and travel introduce risks of cross-contamination.
Even small traces can restart intestinal damage and symptoms. ANB033 could give patients an added layer of protection during those unavoidable exposures and thereby ease the constant pressure of strict gluten-free living.
Researchers continue to assess intestinal healing and symptom severity at the 12-week mark in a second group of patients. They expect initial results early next year. The full findings from the current study will appear at the International Celiac Disease Symposium in Melbourne next month.
The trial involved only 32 patients, so larger studies must confirm safety and lasting benefit. If those trials support the early data, ANB033 could become a meaningful option for people who still face gluten exposure risk despite careful dietary adherence.
The drug would not eliminate the need for a gluten-free diet. Instead, it could make that lifestyle less rigid and less stressful by lowering the consequences of accidental contact.
For the many patients who struggle with the practical and social demands of strict gluten-free living, these early results mark a hopeful step forward.
.jpg)
